SGLT2 inhibitors significantly lowered all-cause and cardiovascular mortality, myocardial infarction, hospitalizations due to heart failure, the risk for new-onset arrhythmias, kidney failure, incidence or worsening nephropathy, macroalbuminuria, lower body weight, blood pressure with a slight increase in the risk of UTI, and genital infections in T2DM patients. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.